MilliporeSigma has begun to offer complete and fully integrated services and products for the development and manufacturing of antibody-drug conjugates (ADCs) from gene sequencing to final drug substance. Products and services include process development and manufacturing of monoclonal antibodies, linker and payload supply and conjugation expertise.

A seamless process from gene sequencing to stability testing of drug products enables customers to reduce development and manufacturing complexity, according to the company. Key benefits of the fully integrated ADC offering include: accelerated time to market; reduced supply chain complexity; streamlined development and manufacturing; and state-of-the-art technologies for manufacturing and conjugation.

While ADCs represent a promising new type of therapy, the corresponding supply chain of monoclonal antibodies, payloads and linkers presents a significant challenge. MilliporeSigma says its new combined offering provides the capabilities, products and expertise to simplify production and accelerate time to market, while managing a complex supply chain.